COVID-19 恢复期血浆：第 2 阶段。
COVID-19 convalescent plasma: phase 2.
机构信息
DeGowin Blood Center, Department of Pathology, University of Iowa Hospitals & Clinics (UIHC), Iowa City, Iowa, USA.
出版信息
Transfusion. 2020 Jun;60(6):1332-1333. doi: 10.1111/trf.15842. Epub 2020 May 12.
Abstract
See editorial on page 1123–1127, in this issue
摘要
见本期第 1123–1127 页社论
相似文献
1
COVID-19 convalescent plasma: phase 2.
Transfusion. 2020 Jun;60(6):1332-1333. doi: 10.1111/trf.15842. Epub 2020 May 12.
2
Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design.
Transfusion. 2020 Jun;60(6):1123-1127. doi: 10.1111/trf.15843. Epub 2020 May 12.
3
Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.
Transfus Clin Biol. 2020 Aug;27(3):167-168. doi: 10.1016/j.tracli.2020.05.002. Epub 2020 Jun 12.
4
Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date.
Br J Haematol. 2020 Jun;189(6):1062-1063. doi: 10.1111/bjh.16780. Epub 2020 May 19.
5
Convalescent Plasma: Promise for COVID-19 Pandemic.
J Coll Physicians Surg Pak. 2020 Jun;30(6):88. doi: 10.29271/jcpsp.2020.Supp1.S88.
6
Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.
JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.
7
The convalescent sera option for containing COVID-19.
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
8
The resurgence of convalescent plasma therapy.
Lancet Haematol. 2020 May;7(5):e353. doi: 10.1016/S2352-3026(20)30117-4.
9
COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies.
Cleve Clin J Med. 2020 Jun;87(6):321-327. doi: 10.3949/ccjm.87a.20047. Epub 2020 May 4.
10
Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
Transfusion. 2020 Aug;60(8):1765-1772. doi: 10.1111/trf.15918. Epub 2020 Jul 6.
引用本文的文献
1
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.
Process Biochem. 2023 Apr;127:66-81. doi: 10.1016/j.procbio.2023.01.018. Epub 2023 Jan 31.
2
Clinical nursing care protocol for convalescent plasma transfusion in patients with COVID-19.
Int J Afr Nurs Sci. 2023;18:100518. doi: 10.1016/j.ijans.2022.100518. Epub 2022 Dec 13.
3
Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Nov;40(9):507-516. doi: 10.1016/j.eimce.2021.01.009.
4
Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.
Transfus Apher Sci. 2022 Dec;61(6):103455. doi: 10.1016/j.transci.2022.103455. Epub 2022 May 11.
5
SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors.
Transfus Apher Sci. 2022 Apr;61(2):103326. doi: 10.1016/j.transci.2021.103326. Epub 2021 Nov 23.
6
WOANet: Whale optimized deep neural network for the classification of COVID-19 from radiography images.
Biocybern Biomed Eng. 2021 Oct-Dec;41(4):1702-1718. doi: 10.1016/j.bbe.2021.10.004. Epub 2021 Oct 23.
7
Convalescent Plasma for Coronavirus Disease 2019: Dose is the Key.
J Transl Int Med. 2021 Jul 9;9(2):68-70. doi: 10.2478/jtim-2021-0029. eCollection 2021 Jun.
8
Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors.
Transfusion. 2021 Jul;61(7):2099-2106. doi: 10.1111/trf.16401. Epub 2021 Apr 15.
9
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.
JMIR Public Health Surveill. 2021 Apr 7;7(4):e25500. doi: 10.2196/25500.
10
Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Feb 11;40(9):507-16. doi: 10.1016/j.eimc.2021.01.013.
Zotero 插件